Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist

Kidney International

Volumn 74, Issue 10, 2008, Pages 1319-1326

  Wenderfer, Scott E ^a   Stepkowski, Stanislaw M ^b   Braun, Michael C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Apoptosis; Glomerulonephritis; Lupus nephritis; Lymphocytes; S1P receptors; Systemic lupus erythematosus

Indexed keywords

[2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL]; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; KRP 203; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLOMERULONEPHRITIS; INTERSTITIAL NEPHRITIS; KIDNEY INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; APOPTOSIS; CHEMOTAXIS, LEUKOCYTE; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; LYMPHOCYTES; MICE; MICE, INBRED MRL LPR; RECEPTORS, LYSOSPHINGOLIPID; SULFHYDRYL COMPOUNDS; SURVIVAL RATE;

EID: 55249113624     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.396     Document Type: Article

References (40)

1. Oates JC, Gilkeson GS. Mediators of injury in lupus nephritis. Curr Opin Rheumatol 2002; 14: 498-503.
2. Cook HT, Botto M. Mechanisms of disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006; 2: 330-337.
3. Austin III HA, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
4. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
5. Kahan BD. FTY720: from bench to bedside. Transplant Proc 2004; 36: 531S-543S.
6. Zheng Y, Voice JK, Kong Y et al. Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes. FASEB J 2000; 14: 2387-2389.
7. Graeler M, Goetzl EJ. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J 2002; 16: 1874-1878.
8. Graeler M, Shankar G, Goetzl EJ. Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate. J Immunol 2002; 169: 4084-4087.
9. Matloubian M, Lo CG, Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360.
10. Mandala S, Hajdu R, Bergstrom J et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-349.
11. Fujita T, Inoue K, Yamamoto S et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo) 1994; 47: 208-215.
12. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004; 4: 1019-1025.
13. Tedesco-Silva H, Mourad G, Kahan BD et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005; 79: 1553-1560.
14. Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140.
15. Daniel C, Sartory NA, Zahn N et al. FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. Mol Immunol 2007; 44: 3305-3316.
16. Kaneko T, Murakami T, Kawana H et al. Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. Biochem Biophys Res Commun 2006; 345: 85-92.
17. Xin C, Ren S, Eberhardt W et al. The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br J Pharmacol 2006; 147: 164-174.
18. Sanna MG, Liao J, Jo E et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004; 279: 13839-13848.
19. Forrest M, Sun SY, Hajdu R et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 2004; 309: 758-768.
20. Koyrakh L, Roman MI, Brinkmann V et al. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005; 5: 529-536.
21. Song J, Matsuda C, Kai Y et al. A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J Pharmacol Exp Ther 2008; 324: 276-283.
22. Shimizu H, Takahashi M, Kaneko T et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 2005; 111: 222-229.
23. Fujishiro J, Kudou S, Iwai S et al. Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. Transplantation 2006; 82: 804-812.
24. Ogawa R, Takahashi M, Hirose S et al. A novel sphingosine-1- phosphate receptor agonist KRP-203 attenuates rat autoimmune myocarditis. Biochem Biophys Res Commun 2007; 361: 621-628.
25. Suzuki S, Li XK, Shinomiya T et al. The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720. Clin Exp Immunol 1997; 107: 103-111.
26. Okazaki H, Hirata D, Kamimura T et al. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol 2002; 29: 707-716.
27. Tawadrous MN, Mabuchi A, Zimmermann A et al. Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat. Transplantation 2002; 74: 602-610.
28. Jo E, Sanna MG, Gonzalez-Cabrera PJ et al. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 2005; 12: 703-715.
29. Watson ML, Rao JK, Gilkeson GS et al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 1992; 176: 1645-1656.
30. Cuvillier O, Edsall L, Spiegel S. Involvement of sphingosine in mitochondria-dependent Fas-induced apoptosis of type II Jurkat T cells. J Biol Chem 2000; 275: 15691-15700.
31. Ruvolo PP. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 2003; 47: 383-392.
32. Paugh SW, Payne SG, Barbour SE et al. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 2003; 554: 189-193.
33. Singer II, Tian M, Wickham LA et al. Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J Immunol 2005; 175: 7151-7161.
34. Fueller M, Wang DA, Tigyi G et al. Activation of human monocytic cells by lysophosphatidic acid and sphingosine-1-phosphate. Cell Signal 2003; 15: 367-375.
35. Gennero I, Fauvel J, Nieto M et al. Apoptotic effect of sphingosine 1-phosphate and increased sphingosine 1-phosphate hydrolysis on mesangial cells cultured at low cell density. J Biol Chem 2002; 277: 12724-12734.
36. Katsuma S, Hada Y, Ueda T et al. Signalling mechanisms in sphingosine 1-phosphate-promoted mesangial cell proliferation. Genes Cells 2002; 7: 1217-1230.
37. Peters H, Martini S, Wang Y et al. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis. Kidney Int 2004; 66: 1434-1443.
38. Inoki I, Takuwa N, Sugimoto N et al. Negative regulation of endothelial morphogenesis and angiogenesis by S1P2 receptor. Biochem Biophys Res Commun 2006; 346: 293-300.
39. Yuen PS, Dunn SR, Miyaji T et al. A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol 2004; 286: F1116-F1119.
40. Wenderfer SE, Ke B, Hollmann TJ et al. C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice. J Am Soc Nephrol 2005; 16: 3572-3582.